ArticleBMC ophthalmology2026
Evaluation of aflibercept treatment outcomes using optical coherence tomography angiography in macular telangiectasia type 1.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the anatomical, functional, and vascular effects of intravitreal aflibercept in macular telangiectasia (MacTel) type 1 using optical coherence tomography angiography (OCTA).
methodsThis retrospective study included nine eyes of nine patients with MacTel type 1 who underwent a single intravitreal aflibercept injection. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and macular vessel density in superficial and deep capillary plexuses (SVD and DVD, respectively) were measured before and one month after treatment using swept-source OCT and OCTA.
resultsMean BCVA improved from 0.4 ± 0.3 to 0.2 ± 0.2 logMAR (p = 0.003) and CMT decreased from 371.4 ± 112 to 237.9 ± 55.1 μm (p = 0.003). Temporal SVD (p = 0.021) and temporal DVD (p = 0.020) showed statistically significant increase. BCVA change showed a strong positive correlation with CMT change (ρ = 0.70, p = 0.034). A moderate negative correlation between the change in BCVA (logMAR) and the change in inferior DVD did not achieve statistical significance (ρ= -0.635, p = 0.066).
conclusionA single intravitreal aflibercept injection led to significant anatomical and functional improvements in MacTel type 1, with a marked increase in vessel density in the temporal quadrant. This study indicates that the characteristics of retinal microvasculature may be modified following aflibercept injection in MacTel type 1 eyes, as observed through OCTA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.